Literature DB >> 18854348

Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B.

T Nagashima, S Minota.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18854348     DOI： 10.1093/rheumatology/ken384

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  14 in total

1.  Unchanged serum viral load and liver function during tocilizumab treatment in a patient with rheumatoid arthritis and hepatitis C virus infection.

Authors:  Takao Nagashima; Akihito Maruyama; Yasuyuki Kamata; Seiji Minota
Journal:  Rheumatol Int       Date:  2011-07-23       Impact factor: 2.631

Review 2.  Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.

Authors:  Francesca De Nard; Monica Todoerti; Vittorio Grosso; Sara Monti; Silvia Breda; Silvia Rossi; Carlomaurizio Montecucco; Roberto Caporali
Journal:  World J Hepatol       Date:  2015-03-27

Review 3.  The role of IL-6 in host defence against infections: immunobiology and clinical implications.

Authors:  Stefan Rose-John; Kevin Winthrop; Leonard Calabrese
Journal:  Nat Rev Rheumatol       Date:  2017-06-15       Impact factor: 20.543

Review 4.  Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.

Authors:  Shunsuke Mori; Shigetoshi Fujiyama
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

Review 5.  Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention.

Authors:  Masaru Kato; Tatsuya Atsumi
Journal:  Rheumatol Int       Date:  2015-11-16       Impact factor: 2.631

Review 6.  Management of rheumatic disease with comorbid HBV or HCV infection.

Authors:  Dimitrios Vassilopoulos; Leonard H Calabrese
Journal:  Nat Rev Rheumatol       Date:  2012-05-08       Impact factor: 20.543

7.  Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.

Authors:  Filip De Keyser
Journal:  Curr Rheumatol Rev       Date:  2011-02

Review 8.  Treatment of rheumatic diseases and hepatitis B virus coinfection.

Authors:  Anna Felis-Giemza; Marzena Olesińska; Katarzyna Świerkocka; Ewa Więsik-Szewczyk; Ewa Haładyj
Journal:  Rheumatol Int       Date:  2014-12-31       Impact factor: 2.631

9.  Biological therapy in arthritis patients with hepatitis B or C infection: a multicenter retrospective case series.

Authors:  Sultana Abdulaziz; Hussein Halabi; Mohammed A Omair; Suzan Attar; Abdullah Alghamdi; Mohammed Shabrawishi; Abdulwahab Neyazi; Haneen Alnazzawi; Nuha Meraiani; Hani Almoallim
Journal:  Eur J Rheumatol       Date:  2017-09-01

10.  Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.

Authors:  Josef S Smolen; Monika M Schoels; Norihiro Nishimoto; Ferdinand C Breedveld; Gerd R Burmester; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Cem Gabay; Allan Gibofsky; Juan Jesus Gomez-Reino; Graeme Jones; Tore K Kvien; Miho Murakami; Neil Betteridge; Clifton O Bingham; Vivian Bykerk; Ernest H Choy; Bernard Combe; Maurizio Cutolo; Winfried Graninger; Angel Lanas; Emilio Martin-Mola; Carlomaurizio Montecucco; Mikkel Ostergaard; Karel Pavelka; Andrea Rubbert-Roth; Naveed Sattar; Marieke Scholte-Voshaar; Yoshiya Tanaka; Michael Trauner; Gabriele Valentini; Kevin L Winthrop; Maarten de Wit; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2012-11-21       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.